Current Report Filing (8-k)
06 Janvier 2023 - 10:31PM
Edgar (US Regulatory)
0001739174 false 0001739174 2023-01-05
2023-01-05 0001739174
PHGE:UnitsEachConsistingOfOneShareOfCommonStockAndOneWarrantEntitlingHolderToReceiveOneHalfShareOfCommonStockMember
2023-01-05 2023-01-05 0001739174
PHGE:CommonStock0.0001ParValueMember 2023-01-05 2023-01-05
0001739174
PHGE:WarrantsEachExercisableForOnehalfOfShareOfCommonStockAtExercisePriceOf11.50PerShareMember
2023-01-05 2023-01-05 iso4217:USD xbrli:shares iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
Form
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported): January 6, 2023
(January
5, 2023)
| |
BiomX Inc. |
|
| |
(Exact
Name of Registrant as Specified in its Charter) |
|
|
Delaware |
|
001-38762 |
|
82-3364020 |
(State
or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
22 Einstein St.,
Floor 4
Ness Ziona,
Israel |
|
7414003 |
| (Address of Principal Executive
Offices) |
|
(Zip
Code) |
Registrant’s telephone number, including area code: (972)
72-394-2377
| |
n/a |
|
| |
(Former name or former address, if changed since
last report) |
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
|
Units, each consisting of one share of Common Stock and one Warrant
entitling the holder to receive one half share of Common
Stock
|
|
PHGE.U |
|
NYSE American |
|
Common Stock, $0.0001 par value
|
|
PHGE |
|
NYSE American |
|
Warrants, each exercisable for one-half of a share of Common Stock,
at an exercise price of $11.50 per share
|
|
PHGE.WS |
|
NYSE American |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensation
Arrangements of Certain Officers.
On January 5, 2023, Jonas Grossman and Dr. Gbola Amusa each
resigned from the Board of Directors (the “Board”) of BiomX Inc.
(the “Company”), for personal reasons, effective immediately. Mr.
Grossman and Dr. Amusa did not advise the Company of any
disagreement with the Company on any matter relating to its
operations, policies or practices. The Company is actively seeking
new candidates to fill the vacancies on the Board.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
BIOMX
INC. |
| |
|
|
| January 6, 2023 |
By: |
/s/ Jonathan Solomon |
| |
|
Name: Jonathan
Solomon |
| |
|
Title: Chief Executive
Officer |
BiomX (AMEX:PHGE)
Graphique Historique de l'Action
De Fév 2023 à Mar 2023
BiomX (AMEX:PHGE)
Graphique Historique de l'Action
De Mar 2022 à Mar 2023
